Active — Not RecruitingPhase 2

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

United States252 participantsStarted 2025-10-24

Plain-language summary

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Ocular hypertension or primary open-angle glaucoma in each eye Exclusion criteria: * History of orthostatic hypotension * Any active ocular disease * Anticipated wearing of contact lenses during study * Contraindication to pupil dilation

What they're measuring

Change from baseline in visual field mean deviation in the study eye at Day 28/Exit.

Timeframe: Assessed at Day 28

Trial details

NCT IDNCT07168902

SponsorBausch & Lomb Incorporated

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-05

View on ClinicalTrials.gov More Glaucoma trials